My ePortfolio Register   

ASH 2017: Immunotherapy for multiple myeloma

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
This content is restricted to members who are registered with ecancer as a healthcare professional.
Please login or register for free to confirm your details.
Published: 12.12.17
Views: 1144

Prof Paul Richardson & Dr Wenming Chen

Dr Paul Richardson from the Dana–Farber Cancer Institute, Boston, U.S.A, chaired an expert discussion with Dr Wenming Chen from Beijing Chaoyang hospital, Beijing, China where they looked at the impact recent data releases, from the 59th annual American Society of Haematology conference in Atlanta, would have on patients living with multiple myeloma.

During this discussion Dr Richardson and Dr Chen discussed the efficacy and safety of long term ixazomib maintenance therapy, the immunotherapy daratumumab as a monotherapy for patients with high-risk smouldering multiple myeloma, and Chimeric Antigen Receptor (CAR) T-cell therapy, specifically looking at CD-19 and B-Cell Maturation Antigen (BCMA) as targets.

For more on the latest haematology news, catch up with all of our ASH 2017 coverage here.

This programme has been supported by an unrestricted educational grant from Takeda

Related videos

follow us

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence